ENDRA Life Sciences Inc reports results for the quarter ended March 31 - Earnings Summary

• ENDRA Life Sciences Inc NDRA.OQ reported a quarterly adjusted loss of $1.86​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-455.00. The lone analyst forecast for the quarter was for a loss of $3.91 per share.

• Reported revenue was zero​; analysts expected zero.

• ENDRA Life Sciences Inc's reported EPS for the quarter was a loss of $1.86​.

• The company reported a quarterly loss of $1.04 million.

• ENDRA Life Sciences Inc shares had fallen by 23.7% this quarter and lost 50.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for ENDRA Life Sciences Inc is $50.00

This summary was machine generated from LSEG data May 15 at 08:48 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)